Department of Biochemistry, University of Washington, Seattle, WA 98195-7742, USA.
Biochimie. 2011 Mar;93(3):570-82. doi: 10.1016/j.biochi.2010.11.015. Epub 2010 Dec 7.
Leishmania parasites cause two million new cases of leishmaniasis each year with several hundreds of millions of people at risk. Due to the paucity and shortcomings of available drugs, we have undertaken the crystal structure determination of a key enzyme from Leishmania major in hopes of creating a platform for the rational design of new therapeutics. Crystals of the catalytic core of methionyl-tRNA synthetase from L. major (LmMetRS) were obtained with the substrates MgATP and methionine present in the crystallization medium. These crystals yielded the 2.0 Å resolution structure of LmMetRS in complex with two products, methionyladenylate and pyrophosphate, along with a Mg(2+) ion that bridges them. This is the first class I aminoacyl-tRNA synthetase (aaRS) structure with pyrophosphate bound. The residues of the class I aaRS signature sequence motifs, KISKS and HIGH, make numerous contacts with the pyrophosphate. Substantial differences between the LmMetRS structure and previously reported complexes of Escherichia coli MetRS (EcMetRS) with analogs of the methionyladenylate intermediate product are observed, even though one of these analogs only differs by one atom from the intermediate. The source of these structural differences is attributed to the presence of the product pyrophosphate in LmMetRS. Analysis of the LmMetRS structure in light of the Aquifex aeolicus MetRS-tRNA(Met) complex shows that major rearrangements of multiple structural elements of enzyme and/or tRNA are required to allow the CCA acceptor triplet to reach the methionyladenylate intermediate in the active site. Comparison with sequences of human cytosolic and mitochondrial MetRS reveals interesting differences near the ATP- and methionine-binding regions of LmMetRS, suggesting that it should be possible to obtain compounds that selectively inhibit the parasite enzyme.
利什曼原虫寄生虫每年导致 200 万例新的利什曼病病例,数亿人面临风险。由于现有药物的稀缺性和不足,我们已经着手确定主要利什曼原虫的一种关键酶的晶体结构,希望为新疗法的合理设计创建一个平台。含有底物 MgATP 和蛋氨酸的主要利什曼原虫(LmMetRS)甲硫氨酰-tRNA 合成酶的催化核心晶体在结晶介质中获得。这些晶体产生了与两个产物,甲硫氨酰腺苷酸和焦磷酸结合的 LmMetRS 的 2.0 Å 分辨率结构,以及桥接它们的 Mg(2+)离子。这是第一个具有焦磷酸结合的 I 类氨酰-tRNA 合成酶(aaRS)结构。I 类 aaRS 特征序列基序 KISKS 和 HIGH 的残基与焦磷酸盐形成许多接触。尽管其中一种类似物仅与中间产物相差一个原子,但与先前报道的大肠杆菌 MetRS(EcMetRS)与甲硫氨酰腺苷酸中间产物类似物的复合物相比,LmMetRS 结构观察到大量差异。这些结构差异的来源归因于 LmMetRS 中产物焦磷酸盐的存在。根据 Aquifex aeolicus MetRS-tRNA(Met)复合物分析 LmMetRS 结构表明,需要对酶和/或 tRNA 的多个结构元素进行重大重排,以使 CCA 受体三核苷酸到达活性位点的甲硫氨酰腺苷酸中间产物。与人类细胞质和线粒体 MetRS 的序列比较显示,LmMetRS 的 ATP 和蛋氨酸结合区域附近存在有趣的差异,这表明有可能获得选择性抑制寄生虫酶的化合物。